Pfizer bankrolls an oncolytics biotech upstart with an eye on a future buyout
Pfizer is bankrolling a new oncolytic virus startup, taking a 50% stake in the cancer drug outfit while holding an option to buy it if the founders appear to be on the right R&D track.
The upstart is Ignite Immunotherapy, based in Alameda, CA, which is being launched by a group of experienced oncolytics hands. Berkeley adjunct professor David Kirn, the CEO of 4D Molecular Therapeutics, is the co-founder, along with Berkeley’s Dave Schaffer.
Unlock this article instantly by becoming a free subscriber.
You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.